(Q54446298)

English

Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.

scientific article published in March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

Pseudomonas aeruginosa

0 references

United States of America

0 references

intensive care unit

1 reference

based on heuristic

inferred from title

Acinetobacter baumannii

1 reference

based on heuristic

inferred from title

Escherichia coli

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

2

object named as

Joseph L Kuti

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

David P Nicolau

3

object named as

David P Nicolau

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

author name string

C Andrew DeRyke

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

27

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

333-342

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Does the dose matter?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Intermittent bolus dosing of ceftazidime in critically ill patients.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Application of fluoroquinolone pharmacodynamics

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.333

21 January 2018

Identifiers

10.1592/PHCO.27.3.333

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/17316145

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54446298&oldid=2144418543"